Edited by Darren W. Davis, Roy S. Herbst, and James L. Abbruzzese. 841 pp., illustrated. Boca Raton, FL, CRC Press, 2008. $199.95. ISBN 978-0-8493-2799-5.
This year began with the death of Judah Folkman, an enormousblow to the medical and scientific communities. It was in theJournal, in 1971, that Folkman published the seminal frameworkfor his ideas about what is now known as tumor angiogenesis.The importance of angiogenesis in preclinical cancer modelswas reproduced in hundreds of laboratories worldwide, culminatingin 2004 in the first antiangiogenic therapy approved by theFood and Drug Administration (FDA) to treat cancer, bevacizumab(Avastin, Genentech). Although this monoclonal antibody is thefirst in what we hope will be a useful class of therapeutics,antiangiogenic monotherapy has . . . [Full Text of this Article]
Previous
